Clinical Trial Update: A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

View source ↗

Summary

This clinical trial update notes the termination of a prospective observational multicenter study evaluating the use of Eylea (aflibercept) for wet age-related …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Eylea (aflibercept) (aflibercept)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Wet Age-related Macular Degeneration | Status: TERMINATED